Jerusalem, 8 June, 2025 (TPS-IL) — CollPlant Biotechnologies announced it has secured a European patent allowance for its rhCollagen-based injectable fillers and regenerative breast implants. The patent, valid through 2041, strengthens the Israeli startup’s position in the $6.3 billion soft tissue filler and $3 billion breast implant markets.
The company’s technology uses non-animal-derived recombinant human collagen to develop 3D biocompatible, degradable implants aimed at natural tissue regeneration. CEO Yehiel Tal called the patent a key milestone in expanding CollPlant’s reach in Europe, a strategic target market for the company’s regenerative medicine solutions.